CREATIVE MEDICAL TECHNOLOGY
CELZNASDAQ🏆 #5227 by market capEarnings Nov 5US Equity
$0.71▼ $0.00 (−0.14%)
After hours · at closeTrack CELZ
Get earnings, price moves & breaking news on Telegram
24h▼ 0.1%
7d▼ 7.6%
14d▼ 7.4%
30d▼ 24.8%
ytd▼ 63.2%
1y▼ 81.3%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
-45.5%
Declining
📊Gross Margin
-1732.4%
Thin
💵FCF Margin
-196723.9%
Thin
⚖️P/S Ratio
593.7x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.71 – $0.72
- 52-Week Range
- $0.62 – $6.25
- Volume (shares)
- 216
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $6,000
- Last Q Revenue
- —
- P/E Ratio
- -0.3
- P/S Ratio
- 593.7x
- EPS (TTM)
- $-1.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +44.3%
CREATIVE MEDICAL TECHNOLOGY
CELZFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6K▼ −45.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
63.4%▲ +5.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▲ +6.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$6M▲ +10.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.4M▲ +44.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$1M YoY
StockOtter · stockotter.spaceAbout CREATIVE MEDICAL TECHNOLOGY
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.